Literature DB >> 23729298

The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson's disease.

Hardy J Rideout1, Leonidas Stefanis.   

Abstract

Leucine-rich repeat kinase 2 (LRRK2) is a large, widely expressed protein of largely unknown function. Mutations in the gene encoding LRRK2 have been linked to multiple diseases, including a prominent association with familial and sporadic Parkinson's disease (PD), as well as inflammatory bowel disorders such as Crohn's disease. The LRRK2 protein possesses both kinase and GTPase signaling domains, as well as multiple protein interaction domains. Experimental studies in both cellular and in vivo models of mutant LRRK2-induced neurodegeneration have given clues to potential function(s) of LRRK2, yet much remains unknown. For example, while it is known that intact kinase and GTPase activity are required for mutant forms of the protein to trigger cell death, the specific targets of these enzymatic activities that mediate the death of neurons are not known. In this review, we discuss the evidence linking LRRK2 to various cellular/neuronal activities such as extrinsic death and inflammatory signaling, lysosomal protein degradation, the cytoskeletal system and neurite outgrowth, vesicle trafficking, mitochondrial dysfunction, as well as multiple points of interaction with several other genes linked to the pathogenesis of PD. In order for more effective therapeutic strategies to be envisioned and implemented, the mechanisms underlying LRRK2-mediated neurodegeneration need to be better characterized. Furthermore, insights into LRRK2-associated PD pathogenesis can potentially advance our understanding of the more common sporadic forms of PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23729298     DOI: 10.1007/s11064-013-1073-5

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  138 in total

1.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.

Authors:  Ana Maria Cuervo; Leonidas Stefanis; Ross Fredenburg; Peter T Lansbury; David Sulzer
Journal:  Science       Date:  2004-08-27       Impact factor: 47.728

2.  α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells.

Authors:  Kazunari Kondo; Saemi Obitsu; Reiko Teshima
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

3.  Genetic animal models for evaluating the role of autophagy in etiopathogenesis of Parkinson disease.

Authors:  M Lenard Lachenmayer; Zhenyu Yue
Journal:  Autophagy       Date:  2012-08-29       Impact factor: 16.016

Review 4.  Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.

Authors:  Kostas Vekrellis; Leonidas Stefanis
Journal:  Expert Opin Ther Targets       Date:  2012-04       Impact factor: 6.902

5.  JNK regulates FoxO-dependent autophagy in neurons.

Authors:  Ping Xu; Madhumita Das; Judith Reilly; Roger J Davis
Journal:  Genes Dev       Date:  2011-02-15       Impact factor: 11.361

6.  RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF-kappa B and is processed during apoptosis.

Authors:  Etienne Meylan; Fabio Martinon; Margot Thome; Michael Gschwendt; Jürg Tschopp
Journal:  EMBO Rep       Date:  2002-11-21       Impact factor: 8.807

7.  G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization.

Authors:  Tatiana D Papkovskaia; Kai-Yin Chau; Francisco Inesta-Vaquera; Dmitri B Papkovsky; Daniel G Healy; Koji Nishio; James Staddon; Michael R Duchen; John Hardy; Anthony H V Schapira; J Mark Cooper
Journal:  Hum Mol Genet       Date:  2012-06-26       Impact factor: 6.150

8.  Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.

Authors:  David Ramonet; João Paulo L Daher; Brian M Lin; Klodjan Stafa; Jaekwang Kim; Rebecca Banerjee; Marie Westerlund; Olga Pletnikova; Liliane Glauser; Lichuan Yang; Ying Liu; Deborah A Swing; M Flint Beal; Juan C Troncoso; J Michael McCaffery; Nancy A Jenkins; Neal G Copeland; Dagmar Galter; Bobby Thomas; Michael K Lee; Ted M Dawson; Valina L Dawson; Darren J Moore
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

9.  Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy.

Authors:  Maria Xilouri; Tereza Vogiatzi; Kostas Vekrellis; David Park; Leonidas Stefanis
Journal:  PLoS One       Date:  2009-05-13       Impact factor: 3.240

10.  Exosomal cell-to-cell transmission of alpha synuclein oligomers.

Authors:  Karin M Danzer; Lisa R Kranich; Wolfgang P Ruf; Ozge Cagsal-Getkin; Ashley R Winslow; Liya Zhu; Charles R Vanderburg; Pamela J McLean
Journal:  Mol Neurodegener       Date:  2012-08-24       Impact factor: 14.195

View more
  30 in total

1.  The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm.

Authors:  A R Esteves; M G-Fernandes; D Santos; C Januário; S M Cardoso
Journal:  Mol Neurobiol       Date:  2014-11-15       Impact factor: 5.590

2.  Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene.

Authors:  Xiao-Xia Li; Qin Liao; Huan Xia; Xin-Ling Yang
Journal:  Exp Ther Med       Date:  2015-07-27       Impact factor: 2.447

Review 3.  The association between the LRRK2 G2385R variant and the risk of Parkinson's disease: a meta-analysis based on 23 case-control studies.

Authors:  Cheng-Long Xie; Jia-Lin Pan; Wen-Wen Wang; Yu Zhang; Su-Fang Zhang; Jing Gan; Zhen-Guo Liu
Journal:  Neurol Sci       Date:  2014-07-16       Impact factor: 3.307

Review 4.  Psychosis in Parkinson's Disease: A Lesson from Genetics.

Authors:  Efthalia Angelopoulou; Anastasia Bougea; Sokratis G Papageorgiou; Chiara Villa
Journal:  Genes (Basel)       Date:  2022-06-20       Impact factor: 4.141

Review 5.  Autophagy in Parkinson's Disease.

Authors:  Xu Hou; Jens O Watzlawik; Fabienne C Fiesel; Wolfdieter Springer
Journal:  J Mol Biol       Date:  2020-02-13       Impact factor: 5.469

Review 6.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Authors:  David S Goldstein; Irwin J Kopin; Yehonatan Sharabi
Journal:  Pharmacol Ther       Date:  2014-06-16       Impact factor: 12.310

Review 7.  ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.

Authors:  Manish Verma; Erin K Steer; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2013-11-10

Review 8.  Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.

Authors:  Liesel Goveas; Eugénie Mutez; Marie-Christine Chartier-Harlin; Jean-Marc Taymans
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

Review 9.  Splicing: is there an alternative contribution to Parkinson's disease?

Authors:  Valentina La Cognata; Velia D'Agata; Francesca Cavalcanti; Sebastiano Cavallaro
Journal:  Neurogenetics       Date:  2015-05-16       Impact factor: 2.660

10.  The impact of mitochondrial DNA and nuclear genes related to mitochondrial functioning on the risk of Parkinson's disease.

Authors:  Katarzyna Gaweda-Walerych; Cezary Zekanowski
Journal:  Curr Genomics       Date:  2013-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.